-
1 month ago | 
jnm.snmjournals.org | Gary A. Ulaner |Jason Lewis |Ola Landgren |Molecular Imaging
Currently, the determination of disease burden in multiple myeloma is suboptimal. Myeloma cells may not secrete abnormal immunoglobulins or free light chains, limiting blood and urinary analysis (1). Imaging by radiography and MRI is limited, and approximately 30% of myeloma lesions are not appreciable by 18F-FDG PET (2). Bone marrow biopsies are also limited by the limited sites that can be sampled (3). Thus, better methods of detecting, localizing, and quantitating myeloma cells are needed.
-
Jan 8, 2025 | 
ejnmmires.springeropen.com | Molecular Imaging
This study included 1,110 patients (mean ± standard deviation [SD] age: 69.31 ± 9.44 years; men/women = 437/673) who underwent [18F]FMM brain PET for the differential diagnosis of dementia at our institution between June 2017 and June 2024. The Institutional Review Board of Ajou University approved the clinical methodology of this retrospective study (approval code: AJOUIRB-DB-2024-435). Due to the retrospective design and low risk to participants, the need for formal informed consent was waived.
-
Jan 7, 2025 | 
bjui-journals.onlinelibrary.wiley.com | David Chen |Prostate Theranostics |Molecular Imaging |Siyu Huang
Corresponding Author David C. Chen Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Department of Urology, Austin Health, Melbourne, Victoria, Australia Correspondence: David C.
-
Nov 1, 2024 | 
jnm.snmjournals.org | Molecular Imaging
In the article “PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study,” by Civan et al. (J Nucl Med. 2023;64:372–375), in the subsection PSMA RLT Absorbed Dose and Efficacy, the fourth sentence provides the mean residence time of the lesions [not the mean effective half-life of the lesions]. The authors regret the error.
-
Nov 1, 2024 | 
jnm.snmjournals.org | Molecular Imaging
The cost of “1 size fits all”: Stabin provides perspective as both a cancer survivor and nuclear medicine professional on the importance of patient-individualized approaches to radiopharmaceutical therapies. Page 1661Discussions with leaders: Michal Horný discusses his research on the changing contribution of medical imaging to total U.S. health care costs.
-
Oct 1, 2024 | 
jnm.snmjournals.org | Molecular Imaging
AI and scientific writing: Buvat and Weber challenge chatbots to write, review, and revise a medical manuscript and, based on the results, suggest revised editorial policies on these evolving technologies. Page 1499RELAINCE and prostate cancer: Wong and colleagues summarize a recent conference presentation on the relevance and application of the SNMMI Recommendations for Evaluation of Artificial Intelligence for Nuclear Medicine in prostate cancer care and theranostics.
-
Oct 1, 2024 | 
jnm.snmjournals.org | Molecular Imaging
In the article “First-in-Human Evaluation of 18F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B,” by Wakabayashi et al. (J Nucl Med. 2022;63:1919–1924), there were errors in Figure 5B. The wild-type plasma value in the figure should be 3 ± 1 instead of 5 ± 3, and the corresponding legend should state that “For the radiometabolite, the ratio of brain-to-plasma concentration was 0.3 [not 0.2] in wild-type and 4.0 in BCRP and P-gp knockout mice.
-
Sep 18, 2024 | 
ejnmmires.springeropen.com | Molecular Imaging
The patient data used in the current study have been described in detail previously [11]. We utilized a sub-cohort of this previous study, including only subjects where ECG-gated 15O-water data were available. All patients were diagnosed with asymptomatic severe degenerative and chronic mitral regurgitation, as according to echocardiographic criteria. Subjects with more than mild concomitant valve diseases were excluded.
-
Sep 4, 2024 | 
link.springer.com | Clinical Diabetology |Molecular Imaging
This is a preview of subscription content, to check access. Get 10 units per month Download Article/Chapter or eBook 1 Unit = 1 Article or 1 Chapter Cancel anytime Price excludes VAT (USA) Tax calculation will be finalised during checkout. Instant access to the full article PDF.
-
Aug 21, 2024 | 
medicalxpress.com | Molecular Imaging
A new molecular imaging technique that pairs a novel tracer with a next-generation PET/CT scanner can identify neuroblastoma in children with high sensitivity, requiring a scan time of only minutes and no sedation or anesthesia. With its ability to accurately diagnose neuroblastoma, this technique, known as 18F-MFBG LAFOV PET/CT, has the potential to impact therapeutic decision-making for children with this disease. This research is published in the The Journal of Nuclear Medicine.
